Abdominal scintigraphy using99mTc-HMPAO-labelled leucocytes in patients with seronegative spondylarthropathies without clinical evidence of inflammatory bowel disease

1996 ◽  
Vol 23 (3) ◽  
pp. 243-246 ◽  
Author(s):  
J. C. Alonso ◽  
F. J. Lopez-Longo ◽  
J. L. Lampreave ◽  
C. M. Gonz�lez ◽  
O. Vegazo ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Evidence ◽  
Labelled Leucocytes ◽  
Inflammatory Bowel ◽  
Abdominal Scintigraphy ◽  
Seronegative Spondylarthropathies

Experimental and Clinical Evidence of Endothelial Dysfunction in Inflammatory Bowel Disease

2020 ◽  
Vol 26 (30) ◽  
pp. 3733-3747 ◽  
Author(s):  
Mariana Ferreira-Duarte ◽  
Joana Beatriz Sousa ◽  
Carmen Diniz ◽  
Teresa Sousa ◽  
Margarida Duarte-Araújo ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Endothelial Dysfunction ◽  
Bowel Disease ◽  
Clinical Evidence ◽  
High Cardiovascular Risk ◽  
Considerable Evidence ◽  
Chronic Inflammatory Condition ◽  
Inflammatory Bowel ◽  
Repurposed Drugs ◽  
Main Effects

The endothelium has a crucial role in proper hemodynamics. Inflammatory bowel disease (IBD) is mainly a chronic inflammatory condition of the gastrointestinal tract. However, considerable evidence points to high cardiovascular risk in patients with IBD. This review positions the basic mechanisms of endothelial dysfunction in the IBD setting (both clinical and experimental). Furthermore, we review the main effects of drugs used to treat IBD in endothelial (dys)function. Moreover, we leave challenging points for enlarging the therapeutic arsenal for IBD with new or repurposed drugs that target endothelial dysfunction besides inflammation.

Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence

2017 ◽  
Vol 10 (4) ◽  
pp. 391-400 ◽  
Author(s):  
Sean McConachie ◽  
Sheila M. Wilhelm ◽  
Pramodini B. Kale-Pradhan
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Evidence ◽  
Inflammatory Bowel

Clinical Evidence for Mobilization of Very Small Embryonic/Epiblast Like Stem Cells (VSEL-SCs) in Patients With Inflammatory Bowel Disease

2011 ◽  
Vol 140 (5) ◽  
pp. S-656
Author(s):  
Wojciech M. Marlicz ◽  
Wojciech Blogowski ◽  
Edyta Paczkowska ◽  
Magda Kucia ◽  
Malgorzata Lawniczak ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Stem Cells ◽  
Bowel Disease ◽  
Clinical Evidence ◽  
Inflammatory Bowel

Targeting Leukocyte Trafficking in Inflammatory Bowel Disease: What Is the Clinical Evidence?

2015 ◽  
Vol 33 (Suppl. 1) ◽  
pp. 95-104
Author(s):  
Reena Khanna ◽  
Mahmoud H. Mosli ◽  
Brian G. Feagan
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Evidence ◽  
Cellular Migration ◽  
Leukocyte Trafficking ◽  
Intestinal Tissue ◽  
Efficacy Data ◽  
Inflammatory Bowel ◽  
Inflammatory Drugs ◽  
Novel Targets

Since the cause of inflammatory bowel disease (IBD) is unknown, therapy has traditionally been based on the empiric use of anti-inflammatory drugs. However, the recent identification of specific mechanisms that regulate cellular migration into inflamed intestinal tissue has provided novel targets for drug development. In this article, we discuss these mechanisms and review emerging safety and efficacy data regarding use of selective inhibitors of leukocyte trafficking for the treatment of IBD.

scholarly journals Clinical evidence for allergy in orofacial granulomatosis and inflammatory bowel disease

2013 ◽  
Vol 3 (1) ◽  
pp. 26 ◽  
Author(s):  
Pritash Patel ◽  
Jonathan Brostoff ◽  
Helen Campbell ◽  
Rishi M Goel ◽  
Kirstin Taylor ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Evidence ◽  
Orofacial Granulomatosis ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document